









Markets
/
Stocks
/
nasdaq-prfx
/

PainReform Ltd

PRFX

1.480USD

+0.060+4.23%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.18MMarket Cap

LossP/E TTM



PainReform Ltd

1.480

+0.060+4.23%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

134 / 175

Overall Ranking

606 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

PAINREFORM LTD is a Israel-based pharmaceutical Company. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 65.92.

Overvalued

The company’s latest PE is -0.05, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 221.75K shares, decreasing 16.07% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.21.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Pharmaceuticals industry's average is 7.84.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.04, which is 957.37% below the recent high of -0.47 and -27898.41% above the recent low of -12.35.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 134/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 2.26, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 1.79 and the support level at 1.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.26

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.002

Sell

RSI(14)

51.024

Neutral

STOCH(KDJ)(9,3,3)

64.848

Buy

ATR(14)

0.109

High Vlolatility

CCI(14)

76.856

Neutral

Williams %R

66.667

Sell

TRIX(12,20)

-0.408

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.398

Buy

MA10

1.394

Buy

MA20

1.468

Buy

MA50

1.468

Buy

MA100

1.653

Sell

MA200

2.332

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 11.02%, representing a quarter-over-quarter decrease of 58.44%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bladeranger Ltd

178.77K

Medica Venture Partners

13.72K

+0.01%

L.I.A. Pure Capital Ltd

10.42K

XT Holdings Ltd

4.44K

+24.96%

Osaic Holdings, Inc.

193.00

SBI Securities Co., Ltd.

6.00

Virtu Americas LLC

-100.00%

Susquehanna International Group, LLP

-100.00%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.97, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.